Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
Copyright 2001 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2001
To the Editor: Cyclooxygenase-2 inhibitors
such as celecoxib (Celebrex) are generally presumed to have a lower risk of
causing complicated peptic ulcers and other serious GI toxicity than other
nonsteroidal anti-inflammatory drugs (NSAIDs).
The full data from the CLASS trial,1
which are publicly available on the FDA Web site,2
call these beliefs into question.3 The FDA
found that "For upper GI safety, and also for global safety, there does not
appear to be any meaningful advantage for Celebrex."4
Wright JM, Perry TL, Bassett KL, Chambers GK. Reporting of 6-Month vs 12-Month Data in a Clinical Trial of Celecoxib. JAMA. 2001;286(19):2398-2400. doi:10.1001/jama.286.19.2398